OBJECTIVES: The goal of our poster is to analyse the costs of treatment of the new antiviral therapies against the Hepatitis C virus (HCV) submitted to the Department of Health Technology Assessment of the National Institute of Pharmacy and Nutrition. METHODS: In our analysis, we examined the cost of treatment with the available interferon (IFN)-based and IFN-free therapies based on the current PUPHA database from the official website of National Health Insurance Fund of Hungary. The cost estimates have been made in two different ways both from the payer’s view. The first calculation does not take into account the success of therapy as it’s based on the SPC with the assumption of a complete possible length of the treatment. The second calculation method is based on the sustained virologic response (SVR) which has become the best indication of therapeutic success. RESULTS: Performance-based risk-sharing arrangements should be based on an endpoint which is meaningful both from the payer’s and the patients’ perspective, which can be measured objectively and which depends primarily on the applied therapy. This endpoint is the SVR rate in the treatment of HCV. The SVR rates were between 34,4% and 95% in the relevant clinical studies. The cost of the therapy ranges between 8.4 million HUF and 31 million HUF, if we do not take into account the SVR rates. CONCLUSIONS: Following a more than two decades of intense research, the interferon-free era of hepatitis C treatment has arrived. The availability of IFN-free regimens allows many patients who could not be treated previously because of medical or psychiatric contraindications or an inability to tolerate IFN to receive treatment. Introduction of these new HCV drugs put a financial strain on the payer. The use of performance-based financing is a way to maintain the balance of the budget.